Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment

Erlotinib (Tarceva(®)) is a drug used for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations. Since EGFR is expressed in the skin, EGFR inhibitors commonly develop cutaneous side effects such as acneiform eruption, paronychia, telangiectasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, En Hyung, Kim, Dong Min, Lee, Ji Yeoun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110603/
https://www.ncbi.nlm.nih.gov/pubmed/35508798
http://dx.doi.org/10.1007/s13555-022-00739-5
_version_ 1784709137149460480
author Kim, En Hyung
Kim, Dong Min
Lee, Ji Yeoun
author_facet Kim, En Hyung
Kim, Dong Min
Lee, Ji Yeoun
author_sort Kim, En Hyung
collection PubMed
description Erlotinib (Tarceva(®)) is a drug used for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations. Since EGFR is expressed in the skin, EGFR inhibitors commonly develop cutaneous side effects such as acneiform eruption, paronychia, telangiectasias, and abnormal eyelash growth. A 56-year-old man and a 46-year-old man visited the dermatology clinic complaining of yellowish papuloplaques and acneiform eruption on the face. They had been treated with erlotinib for lung cancer. Since patients using EGFR inhibitors are increasing, physicians should be aware that xanthomatous change can occur in severe acneiform eruptions after erlotinib treatment.
format Online
Article
Text
id pubmed-9110603
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-91106032022-05-18 Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment Kim, En Hyung Kim, Dong Min Lee, Ji Yeoun Dermatol Ther (Heidelb) Case Report Erlotinib (Tarceva(®)) is a drug used for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations. Since EGFR is expressed in the skin, EGFR inhibitors commonly develop cutaneous side effects such as acneiform eruption, paronychia, telangiectasias, and abnormal eyelash growth. A 56-year-old man and a 46-year-old man visited the dermatology clinic complaining of yellowish papuloplaques and acneiform eruption on the face. They had been treated with erlotinib for lung cancer. Since patients using EGFR inhibitors are increasing, physicians should be aware that xanthomatous change can occur in severe acneiform eruptions after erlotinib treatment. Springer Healthcare 2022-05-04 /pmc/articles/PMC9110603/ /pubmed/35508798 http://dx.doi.org/10.1007/s13555-022-00739-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Kim, En Hyung
Kim, Dong Min
Lee, Ji Yeoun
Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
title Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
title_full Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
title_fullStr Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
title_full_unstemmed Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
title_short Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment
title_sort perifollicular xanthoma occurring in patients after erlotinib treatment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110603/
https://www.ncbi.nlm.nih.gov/pubmed/35508798
http://dx.doi.org/10.1007/s13555-022-00739-5
work_keys_str_mv AT kimenhyung perifollicularxanthomaoccurringinpatientsaftererlotinibtreatment
AT kimdongmin perifollicularxanthomaoccurringinpatientsaftererlotinibtreatment
AT leejiyeoun perifollicularxanthomaoccurringinpatientsaftererlotinibtreatment

Ejemplares similares